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Thesis summary
In this thesis, we investigate whether the implementation of a new blood coagulation
management algorithm had a positive effect in cardiac surgery patients’ health at Triemli
city hospital during the years 2010 - 2014.
Cardiac patients suffer from blood coagulation disorders during their hospitalization.
These disorders are associated with loss of blood, and as a result blood component trans-
fusions are necessary. It is known that transfusions can cause several adverse effects, such
as different types of infections and even death. The coagulation management algorithm is
designed to provide a tool for practitioners to control blood coagulation related disorders.
Our intention is to use the relatively new methododoly called Additive Bayesian network
modelling to come into conclusions about the use of this algorithm. Along with Dr. Sonja
Hartnack, the same dataset will be analysed both with Additive Bayesian networks, but
also with a more traditional analysis.
This thesis consists of three parts.
First, an overview of the disease, introduction to Additive Bayesian networks and dataset,
and conclude to the results and discussion section.
The second part consists of Manuscript I, an analysis performed by Dr. Sonja Hartnack.
Basic descriptive statistics and univariable analysis is used along with multicolinearity
and variance inflation factors checks.
The first approach consists of a continuity-corrected log transformation of the response
and the importance of each predictor in the model is considered in form of R2 values
which is the ratio of the explained to the total variance in regression modelling. Point
estimates and 95% confidence intervals are obtained by bootstrapping.
As the response variable contained an excessive amount of zeros, a second approach with
a hurdle model was performed with the same predictors. Additionally, to assess the
association between potential risk factors and the incidence of infections postoperatively,
a generalized linear model with a binomial link and logit function was chosen.
The third part of this thesis consists of Manuscript II, which describes modelling the
data with Additive Bayesian networks. This analysis was performed by me, along with
Dr. Sonja Hartnack. Two heuristic searches were ran for each period, resulting in 4
different final structures. The first two, describing the multivariate behaviour of blood
and coagulation products, and the second two describing patient complications.
All analyses were constatly supervised and assisted by both of my supervisors, Professor
Dr. Reinhard Furrer and Dr. Sonja Hartnack.
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Chapter 1
Introduction
1.1 Cardiac surgery and blood coagulation disorders
Cardiovascular surgery is the surgery on the heart or great vessels performed by car-
diac surgeons. Frequently, it is done to treat complications of ischemic heart disease,
correct congenital heart disease, or treat valvular heart disease from various causes in-
cluding endocarditis, rheumatic heart disease and atherosclerosis. It also includes heart
transplantation.
Coronary artery bypass grafting (CABG) is the most common type of heart surgery.
CABG improves blood flow to the heart. Surgeons use CABG to treat people who have
severe coronary heart disease (CHD). CHD is a disease in which a waxy substance called
plaque builds up inside the coronary arteries. These arteries supply oxygen-rich blood
to the heart. Over time, plaque can harden or rupture. Hardened plaque narrows the
coronary arteries and reduces the flow of oxygen-rich blood to the heart. This can cause
chest pain or discomfort called angina. If the plaque ruptures, a blood clot can form on
its surface and can mostly or completely block blood flow through a coronary artery. This
is the most common cause of a heart attack. Over time, ruptured plaque also hardens
and narrows the coronary arteries.
During CABG, a healthy artery or vein from the body is connected (Figure 1.1), or
grafted, to the blocked coronary artery. The grafted artery or vein bypasses the blocked
portion of the coronary artery. This creates a new path for oxygen-rich blood to flow
to the heart muscle. Surgeons can bypass multiple blocked coronary arteries during one
surgery.
In case of cardiac surgery, especially when a life support device is used (Figure 1.2), it
often results in increased bleeding due to blood coagulation disorders. Coagulation, also
known as clotting is the process by which the blood changes to gel, forming a clot. It
can potentially result in hemostasis, the cessation of blood loss from a damaged vessel,
followed by repair.
As a result of bleeding, there is an increased need for transfusion of the various blood
products, such as fresh frozen plasma, platelets and red blood cells. Whole blood is rarely
used for transfusion. Blood component therapy makes clinical sense as most patients need
a specific element of blood, and the dose can be optimized.
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Figure 1.1: Illustration B shows how vein and artery bypass grafts are attached to the
heart. Source: National Heart, Lung, and Blood Institute; National Institutes of Health;
U.S. Department of Health and Human Services.
Figure 1.2: Heart and lung machine.
Source: National Heart, Lung, and Blood Institute; National Institutes of Health; U.S.
Department of Health and Human Services.
These coagulation disorders are multifactorial. Preoperative administration of platelet-
inhibiting drugs, reduction of coagulation factors, fibrinolysis and platelet dysfunction
due to the use of life support device are to be mentioned as the main causes.
Transfusions are associated with several complications that affects patients. Several types
of infections such as pulmonary and sepsis, negative transfusion reactions, acute lung
injury and eventually mortality.
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Doctors, in order to control the adverse effects of transfusions, use functional coagulation
tests, such as Thromelastometry and Platelet Aggregometry. These tests allow for timely
detection of preoperative coagulation disorders. Coagulation management algorithms
based on these tests could possibly reduce perioperative transfusion needs and the negative
results associated with it.
1.2 The coagulation management algorithm
In 2012, a coagulation management algorithm (Figure 1.3) was implemented in cardiac
surgery patients in Triemli city hospital in Zurich. It has been carefully designed to offer
doctors an optimization tool for controlling blood coagulation disorders.
Values from coagulation tests now are been utilized and guidelines based on thresholds
have to be followed by practitioners. These thresholds provide suggested doses of clotting
products to treat patients.
The algorithm consists of 4 hospitalization periods: Pre-Intervention, Protamine cycle,
Post-Intervention A and Post-Intevention B. The column Measurements contains values
that result from standard coagulation lab and diagnostic tools. The evaluation stage
provides thresholds corresponding to these values. Lastly, column Measures gives the
suggested action that a doctor has to follow given the previous evidence.
Standard coagulation lab measurements
Starting from the Pre-Intevention stage, three measurements result from standard coag-
ulation lab tests. Prothrombin time (PT) is the primary assay used in monitoring oral
anticoagulant therapy. To produce a result, thromboplastin is added to the blood sample
to activate coagulation. This causes a blood clot to form. The time it takes for this clot
to form is measured in seconds and is known as Prothrombin time.
In most countries, blood coagulability is typically expressed in a unit known as the Quick
value. In this case the measured prothrombin time is expressed in relation to the coag-
ulation time of a healthy person. The value obtained is the precentage of the standard
value. In a person not receiving oral anticoagulation medication the normal Quick value
is between 70% and 100%.
Fibrinogen, or factor I, is a blood plasma protein that is made in the liver. Fibrinogen
is one of 13 coagulation factors responsible for normal blood clotting. When there is an
injury and bleeding occurs, the body forms a blood clot through a series of steps. In one
of the last steps, soluble fibrinogen is converted into insoluble fibrin threads that crosslink
together to form a net that stabilizes and adheres at the injury site until the area has
healed.
Platelets (Figure 1.4) are disk shaped cell fragments and 2-4 µm in diameter. Around
150000 and 400000 are present in each cubic millimeter of blood. The inner surface of
blood vessels is lined with a thin layer of cells that under normal situations produce
messengers that inhibit platelet activation. When this thin layer is injured, collagen is
exposed, releasing other factors to the bloodstream which attracts platelets to the wound
site. When the platelets are activated, they clump together to form a platelet plug
3
Figure 1.3: The coagulation management algorithm.
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releasing their contents. The released contents of the platelets activate other platelets
and also interact with other coagulation factors.
Figure 1.4: Platelet activation @2010 MedicineNet, Inc.
For the measurements mentioned above, thresholds are provided and doses Post-Intervention
are suggested to be followed.
Sonoclot measurements in seconds
Sonoclot is a coagulation and platelet function analyzer and is used to monitor activated
clotting time (ACT) measured in seconds. Most common activators are kaolin (kACT)
and glass bead (gbACT) to initiate contanct activation. During surgery, the ACT is kept
above a lower time limit, a limit which most people will not form blood clots.
Clopidogrel is an oral medication that is used to reduce the risk of heart disease and stroke
on those patients at high risk. Onset of effects is about 2 hours and lasts for 5 days.
Multiplate ADP tests platelet function in whole blood. This test can be used to diagnose
platelet disorders, monitor antiplatelet therapy and is also investigated as a potential
predictor of transfusion requirements and bleeding risk in cardiac surgery. Adenosine
diphosphate (ADP) is a platelet agonist. When it is added to saline-diluted whole blood
in the test cuvette, it stimulates the ADP receptors on platelets, activating the platelets.
The activation of the platelets leads to shape change and degranulation, and the released
content of the granules further activates the platelets. Activation also induces a confor-
mational change in the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor, giving it high affinity
for fibrinogen. Binding of fibrinogen to GPIIb/IIIa receptors leads to platelet-to-platelet
bridges and results in platelet aggregation. Area under the curve (AUC) is the most
important parameter of this test and is affected by both the height and the slope of the
aggregation curve, and is the best overall measure of platelet activity.
Protamine cycle
In the second panel of Figure 1.3 the use of Protamine is described. During the hospi-
talisation period, an initial dosis of protamine (Protamine Bull) is given to patients to
reverse the effects of heparin. Heparin acts as an anticoagualant factor. It is used to
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decrease the clotting ability of the blood and help prevent harmful clots from forming in
blood vessels.
Patients who remain hospitalized for days and are unable to move, are at a greater risk
of forming clots. Thus, different activation times in seconds (ACT) are monitored and
protamine is given accordingly.
Post Intervention A, B
After surgery, clotting of the blood is keep monitored. Sonoclot tests are again performed
to assess activation clotting time (ACT), clotting rate (CR) and platelet function (PF). As
the healing process has already begun, the suggested doses provided now are Prothrombin
complex concentrate (PCC), Fibrinogen and platelet concentrate (PC).
Implementing the algorithm
Before the implementation of this algorithm, doctors would act independently and take a
decision based on their expert knowledge and experience. Now every doctor has to follow
this strict procedure through out the treatment period of a patient. The algorithm aims
to reduce the in-between variation of the doctor’s decisions and establish a powerful tool
for managing coagulation disorders.
1.3 Goal of Thesis
The goal of this project can be expanded in to two branches related to the people involved
. Questions of clinical nature were asked by Dr. Christof Hofer. His primary interest was
to test whether the implementation of the algorithm had a positive impact on patients’
health. Therefore, the following primary questions should be answered.
1. Was the need of transfusion and clotting products reduced by introducing the co-
agulation management algorithm?
2. Was there a reduction to patients’ complications?
Taking into consideration the two treatment periods, the number of coagulation and blood
products will be compared. Same for the patients’ complications, in form of hospital
mortality, infections, length of hospitalisation and many more.
A statistically significant lower number of products used and less complications in the
period after the implementation will show if the algorithm is indeed working.
Methodology-wise, our interest lies in modelling such a vast and complex dataset, with
a large number of predictors. A new methodology will be used, called Additive Bayesian
networks (ABN) and it will be introduced in the next section. Questions regarding this
methodoly involve:
1. How Additive Bayesian network modelling will perform with a large number of
variables.
2. Choosing the right search algorithm.
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3. Avoid overfitting.
4. Discover the best structure represented by a directed acyclic graph.
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Chapter 2
Statistical Methods
Through out this thesis Additive Bayesian networks (ABN) have been used to model the
data. Based on the classical Bayesian networks, ABNs provide the user a powerful tool
to discover dependencies among variables under the generalized linear modelling frame.
For more information visit http://www.r-bayesian-networks.org.
2.1 Bayesian networks
2.2 Definition
Bayesian networks (Pearl, 1988) are a graphical representation of a multivariate joint
probability distribution that exploits the dependency structure of distributions to describe
them in a compact and natural manner (Friedman and Koller, 2003).
2.3 Components of a Bayesian network
A Bayesian network comprises of two parts. The network structure S and the model
parameters θ.
The network structure is represented by a Directed Acyclic Graph (DAG). Each variable
in the DAG is called node, and the lines connecting the nodes are called arcs. The arcs
provide the marginal and conditional dependencies in the variable domain.
Figure 2.1: The structure.
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The local probabilities are given based on the parents of each node. The parents of a
node pa(Xj) are its predecessors, or simply the nodes that come before it. For example
in Figure 2.1 the parents of node X3 are X1 and X2. X1 and X2 are independent of the
rest of the nodes so no parents are present.
Given the structure and the model parameters, as the definition of Bayesian networks
suggests, we can obtain the join probability of the structure S. The joint probability of
X is the product of all the local arcs in the structure:
P (X) =
n∏
j=1
P (Xj|pa(Xj)).
2.3.1 A popular example
One of the most common applications in Bayesian networks literature is the A.L.A.R.M.
network (Beinlich et al., 1989). The initials stand for A Logical Alarm Reduction Mecha-
nism and is a diagnostic application that implements an alarm message system for patient
monitoring. It calculates probabilitites for a differential diagnosis based on available evi-
dence.
Figure 2.2: The A.L.A.R.M. network.
The medical knowledge is encoded as in Figure 2.2a with 8 diagnoses, 16 findings and 13
intermediate variables. Diagnoses and other qualitative information are at the top level of
the network. These variables have no predecessors and they are assumed to be mutually
independent a priori.
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Figure 2.2a is the true network where is used in literature to create a database of cases
as in Figure 2.2c. Since we are under the Bayesian framework, a prior belief about the
network is encoded in Figure 2.2b. These two sources of information, prior belief and
database, allow us to learn one or more Bayesian networks presented in Figure 2.2d.
To appreciate the effectiveness of the method, we observe that the learned Bayesian
network in Figure 2.2d is very close to the true network Figure 2.2a. Given the evidence
from the database, the prior belief of the investigator was corrected and led to an accurate
respresentation of the true network.
2.4 Additive Bayesian networks
2.4.1 Description
Additive Bayesian networks modelling (ABN) is a new technique which extends the pre-
vious methodology to generalized linear models. The nodes in the structure are not just
variables anymore, but each node represents a generalized linear model. The previous
conditional probabilities are replaced with linear additive contributions of the variables
in the link function space.
Figure 2.3 represents an ABN with 5 variables. Let nodes X1, X2, X5, denoted by a
square to be binary and X3, X4 denoted by a cirle to be continuous. Also, let P (Xi =
1) = 1− P (Xi = 0) and µi the mean of Xi for i = 3, 4.
Figure 2.3: A simple ABN.
X2 is independent of the other nodes. As it is a binary node the interpretation corresponds
to a logistic regression model with no covariates:
log {pi2/(1− pi2)} = β2,0.
The continuous node X4 is conditionally dependent upon X2 so the mean:
µ4 = β4,0 + β4,1X2.
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For the node with the most parents, X1, given that is a binary node and dependent upon
X2, X3, X5 we have:
log {pi1/(1− pi1)} = β1,0 + β1,1X2 + β1,2X3 + β1,3X5.
Additive Bayesian networks were implemented in R with the package abn which currently
supports three types of variables: continuous, binary and count data.
2.4.2 Learning the structure
Previously, the basic structure of an Additive Bayesian network was introduced. Our
objective is to identify a network that represents the data sufficiently well and at the
same time not being overly complex. Theoretically, we could search all possible node
structures resulting from the combination of nodes and select the one that represents the
data the best.
This is computationally not possible because of the vast space of all possible structures.
It has been shown that the number of combinations grow more than exponentially in the
number of nodes.
Table 2.1: Possible DAGS given the number of nodes.
Nodes 1 2 3 4 5 . . . 21
DAGS 1 3 25 543 29281 . . . 1080
Table 2.1 shows the extreme growth of all possible DAGS given a set of nodes. For one
node, we can obtain maximum one possible DAG. For two nodes X1, X2, the first would
be a structure with X1 ← X2, the second would be X1 → X2 and the third is simply the
empty network with no arcs connecting the nodes.
Allowing all nodes to connect with eachother, it is not possible to search for the best
DAG. An immediate solution for this computational problem is to restrict some of the
arcs between nodes before begining the search. In this way we can decrease the number
of combinations that we can search from.
After restricting the number of possible structure down to a sensible number, it is now
time to introduce a method that allows us to select the one that is more likely to generate
the original data in hand. To achieve this we use what are called score based functions. A
desired property of these score based functions is decomposability, which states that the
total score of a structure can be expressed as the sum of individual nodes scores. More
precisely:
Score(D,S) =
n∑
j=1
Score(Xj, Paj, D).
Now being under the Bayesian framework, a possible candidate for this score is marginal
likelihood. With marginal likelihood we can assess the goodness of fit for a structure S.
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Thus, we have
P (S|D) = P (S)P (D|S)
P (D)
,
where, P (D)−1 is the normalization constant which does not depend on S, P (S) is the
prior of a structure S and P (D|S) the marginal likelihood of the structure given the data
D. We assume that all possible structures are equally plausible to be selected, so the
comparison of structures collapses to the comparison of the marginal likelihoods P (D|S)
as given by
P (D|S) =
∫
βA
P (D|S, βA)pi(βA|S)dβA,
where, βA the parameters of the model and pi(βA|S) the prior probability over the param-
eters conditioned over S.
2.4.3 Search algorithm
Using the previously introduced score functions to uncover the best structure for our
data, it is essential, to define an algorithm to search among all possible structures. The
statistical R package abn offers two options of algorithms for different occasions.
Exact search (Koivisto and Sood, 2004) is mainly used when there is only a handful of
variables. It performs an exaustive search across node orderings to identify a globally best
structure. Then bootstrapping is used to control for overfitting. As exact search was not
an option for us, because of the size of the dataset, and we will not get into detail on this
text.
The algorithm that fitted our needs the best was the heuristic search (Heckerman et al.,
1995). Heuristic search is used when the size of the dataset does not allow for an exact
search and identifies a locally best DAG, starting from a initial random structure. This
process is performed multiple times, each time starting from a different initial DAG. At the
end we summarize the results and obtain the final structure. The algorithm is described
next, along with the method to prune the excessive arcs.
Before introducing the steps of the algorithm, it is important to define three search oper-
ators:
– Arc addition: Add a single arc between two nodes.
– Arc deletion: Remove a single arc between two nodes.
– Arc reversal: Reverse the direction of a single arc.
The search algorithm uses the three operators iteratively to reveal the DAG with the
largest score:
– Let op(S,E) the result of applying a legal operation E to the DAG.
– The DAG and op(S,E) differ only by 1 arc.
1. Let S be an initial structure.
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2. Repeat:
– Calculate ∆(E) for each possible legal operation E.
– Let ∆∗ = maxE∆(E) and E∗ = argmaxE∆(E).
– If ∆∗ > 0 then
– Set S = op(S,E∗).
3. Until ∆∗ 6 0.
Each time, the algorithm starting from an initial random DAG, applies all legal operations
on the structure until there is no change in the marginal likelihood ∆. A legal operation
E must not result into a cyclic arc pattern. This search is ran n times, resulting to n
locally best DAGS.
2.4.4 Control for overfitting
Having run n heuristic searches, then the next challenge is to summarise the results
from the n local structures. A single robust structure is constructed from the majority
concensus structure, in other words, only the arcs present in at least 50% of the local
structures are kept and the rest are discarded.
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Chapter 3
The Dataset
3.1 Introduction
For all cardiac surgery patients at Triemli city hospital a database is maintained for
quality assurance. In this database, sociodemographic, disease-release and perioperative
data are filled routinely.
The dataset consisted of two periods, the period before the implementation of the coag-
ulation management algorithm and after the implementation of it with a total of 1754
patients.
Inclusion Criteria: All patients to whom a cardiac surgery in Triemli City hospital was
carried out between the years 2010-2014.
Exclusion Criteria: None
Two periods: The years 2010-2011 are characterized as the before period including 839
patients and 2013-2014 with 915 patients. The datapoints of year 2012 were not used as
this period is considered to be the learning phase of the algorithm.
3.2 Data related problems
The initial dataset contained a substancial amount of missing values in certain variables.
As abn package is not performing with incomplete datasets, these variables had to be
removed. Complete case analysis was made for the rest variables.
Additionally, extreme values were observed in the basic clinical measurements during a
preliminary analysis of the data. It made sense to ask whether these values were to be
trusted for analysis. After consulting with Dr. Christof Hofer, it was concluded that
many observations were not valid. For example, a BMI of 3000 was found. That would
correspond to a person weighing around 10 tons.
After locating all the invalid observations and the indeces were obtained the dataset had
to be corrected. The doctor had to go back to the initial database and look for the correct
datapoints. The correction of the dataset was a time consuming procedure which lasted
around two months since the start of the project.
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3.3 Description
The initial dataset contained around 100 working variables. In this section we are going
to describe the dataset in a compact way considering the large number of variables.
Table 3.1: Basic demographics.
In Table 3.1 we can see some basic demographic variables of the patients for the two
periods. We observe substancially more males than females with mean age to be 66 years
old and higher than the normal weight limit (BMI). Left ventricular ejection fraction
(LVEF) represents how good the heart pumps with a lower threshold to be 50%. Patients
with hypertension c(HYPER) tend to undergo a cardiac surgery as can be seen by the
frequencies. Also, a small number of patients had diabetes (DMins) and insulin was
administered.
Table 3.2: Variable clusters.
Pre-op Medication
ASA, Heparin
Pre-op Lab
Creatinine, Hematocrit
Interventions
Aortic Valve, Cardio Pulmonary Bypass
Interventional times
Duration of anesthesia / Operation
Allogeneic Transfusions
Red Blood Cells, Fresh Frozen Plasma
Platelets
Coagulation Products
Fibrinogen, Prothrombin Complex
General post-op outcomes
Myocardial Infarction, Cerebrovascular Insult
Infections
Pulmonary, Sepsis
Post-op times
ICU / Hospital Length of Stay
Mortality
ICU / Hospital
Table 3.2 presents part of the variables in a compact manner. This clustering was done
by Dr. Christof Hofer based on the nature of each variable. Some examples are given
of what kind of variables each cluster contains. Allogeneic transfusions and coagulation
products are of primary interest. Also, as a secondary endpoint we consider Infections
and Mortality cluster.
The initial 100 variable dataset was reduced to 54 variables for the before period and 47
variables for the after period. This reduction was necessary from a technical point of view
as mentioned before. After an aggreement with the Dr. Christof Hofer non importand
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variables and partially separated binary variables were removed. We were also able to
aggregate some preoperation and postoperation count data to one total summation.
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Chapter 4
Results
In this section we present results in form of DAGS accompanied with regression coefficients
for the two periods. For both searches, the maximum number of parents allowed was 4
due to computational limitations.
4.1 Before period DAG
In Figure 4.1 the final DAG of the blood and coagulation products is presented. This DAG
results from the bigger DAG with 54 nodes. The variables of importance are graphically
subseted and only direct links between them are kept. The blue nodes, except node
FFREE are poisson regression models and the parents of each node the covariates with
the corresponding coefficients.
EURO
FFREE
0.4
BMI
FIBRINOGEN
0.88
COMPAORTA
PCTOTAL
2.36
FFPTOTAL
2.88
OPTIME
0.61
ANATIME
CPBTIME
1.80
HCTPRAE
RBCTOTAL
0.77
HCTPOST
0.55
0.57
0.50
2.94
CELLSAVER
DRAIN24h
1.37
PCC
1.22
1.04 1.07
1.051.16 0.87
1.15
1.27
0.71
0.60
VENTT
1.07
0.03
IPSD
1.29
PULM
3.38
Figure 4.1: Before period blood-coagulation products DAG.
Interpeting these coefficients correspond to a normal generalized linear model. For exam-
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ple, FFPTOTAL node represents the total count of fresh frozen plasma units that was
given to a patient. An arc is connecting FFPTOTAL to HYPER with a coefficient of
8.93. We would say the expected count of fresh frozen plasma units is 9 times higher to
patients with hypertension.
Node FFREE is a binary variable which dichotomize the patients into two groups, one
group that was free of transfusion and the other group not free of transfusion. We ob-
serve a connection to Euroscore (EURO) and the coefficient to be 0.43. Euroscore is a
preoperative score that predicts perioperative mortality. The odds of a patient of been
free of transfusion decrease by 0.57 for each point increase in Euroscore.
4.2 After period DAG
Figure 4.2 shows the DAG for the after period for the blood and coagulation products.
This DAG was again subsetted from the bigger DAG of 47 variables. Interpretation of
the coefficient can be made again in the same way as in the previous DAG.
As noticed, the two DAGs for the two different time periods did not result into the same
models. Given that, they are not directly comparable. The arcs that are denoted with
red color are the common arcs that were presented in the two periods. But again, these
common arcs cannot be compared to test the efficacy of the coagulation algorithm.
EURO
FFREE
0.4
BMI
FIBRINOGEN
0.88
COMPAORTA
PCTOTAL
2.36
FFPTOTAL
2.88
OPTIME
0.61
ANATIME
CPBTIME
1.80
HCTPRAE
RBCTOTAL
0.77
HCTPOST
0.55
0.57
0.50
2.94
CELLSAVER
DRAIN24h
1.37
PCC
1.22
1.04 1.07
1.051.16 0.87
1.15
1.27
0.71
0.60
VENTT
1.07
0.03
IPSD
1.29
PULM
3.38
Figure 4.2: After period blood-coagulation products DAG.
We prefer to focus on how the structure changed, and not just compare coefficients. The
coefficients along with 95% credible intervals for the two periods are available to Dr.
Christof Hofer to make clinical inference.
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Chapter 5
Discussion
Final structures
The models for the two periods resulted to different DAG structures. Thus, direct com-
parison of the two periods cannot be made. The red arcs are presenting the common arcs
in the DAGs between the two periods. Also, these common arcs cannot be compared.
Given these results, we cannot draw coclusions regarding the use of the algorithm in terms
of model coefficients.
A more interesting approach would be to investigate how the structure changed from one
period to another. Carefully controlling for the differences between models, is the total
number of arcs reduced after the use of the algorithm?
It is also worth wondering why we ended up with different structures when using the same
variable domain. Computational limitations did not allow us to increase the limit of par-
ents above 4. A larger number of parents could possibly result to more similar structures,
with intersecting local arcs in nodes between periods. In that situation comparison would
be possible.
Could possibly the two period cohorts were heterogeneous and not been comparable sets
of observations? Different demographic characteristics could have led to this result.
As mentioned before, partially separated binary nodes were removed from the model.
The choice of parameter prior led to posteriors not integrating to unity. After cleaning
up these binaries, the two periods had different number of variables that could be used
for modeling. That is also a candidate of the above results.
Limitations of ABN
The amount of variables in our dataset forced us to limit the search to only 4 variables
and not use the superior exact search. Even with only 4 parents and around 50 variables
in each model, an ad-hoc use of abn’s heuristic search had to be performed. Each single
run of a heuristic search algorithm was taking an excessive amount of time. Adding an
additional parent to the search, R would crash lacking memory resources. It would not
be possible without a server cluster to finish the analysis. Limiting the search to a small
number of parents we might have lost important information through the process.
Additionally, blood and clotting products that were coded as count data, were overdis-
persed and that lead to extremely narrow credible intervals. Currently, there is no way
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to deal with this problem, as abn package does not support a wide range of distributions.
Overfitting After obtaining 170 locally best structures with the heuristic approach, a
summary based on the 50% majority concensus was performed. The distribution of the
frequencies was an inversed bell curve showing that the strong arcs would appear even if
we would have used a more strict threshold as a cutoff value.
Further research on ABN
While exact search with a small number of variables is well established, when there is
more than a handfull of variables in the dataset, problems would start to appear. A more
in depth documentation on heuristic search would be extremely useful, while methods of
dimension reduction before implementing ABNs should be introduced at the same time.
Further investigation is needed in order to deal with problems such as the zero inflated
poisson counts that were mentioned before.
Conclusion
While Additive Bayesian network modelling performs extremely well under a very specific
framework, that is a small number of variables following certain distributions and available
computational resources, more light needs to be shed in more complicated cases like ours.
We, as users of R and statistics need to spread the word around this new methodology. It
can provide solution to the neverending question of multivariable vs multivariate analysis
under the traditional framework of generalized linear models.
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Appendix A
Supplemental Information
A.1 Abbreviations and definitions
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Abbr Expanded-Explained
BMI Body mass index
LVEF Left ventricular ejection fraction
COLD Chronic obstructive lung disease
KREAprae creatinine pre-operation
GOTprae Liver enzyme pre-operation
GPRprae Liver enzyme pre-operation
LDHprae Liver enzyme pre-operation
DMins Diabetes Insulin
DMoral Diabetes oral medication
ASA Acetylsalicylic Acid Aspirin
CLOP Clopidogrel at Operation
ALTCt Other antiplatelet drugs at operation
ExASA All antiplatelet drugs at operation
DUAL Dual antiplatelet therapy at operation
LIQ Heparin Liquemin pre operation
STATUS urency of operation
CABG Coronary artery bypass grafting
CABGno Number of Coronary artery bypass grafting
AKE Aortic valve replacement
COMP Composite Graft
COMB Combined procedures
MKR Mitral valve replacement
AORTA Aortic graft
OTHER Other operations
ReDO Re-operation after previous cardiac operation
CPB Cardiopulmonary bypass
CONV Convertion to CPB
VALVE Different cardiac valves
OPTIME Duration of operation
ANATIME Time anaesthetized
CPBTIME Time needed for cardiopulmonary bypass
CROSSTIME TIme of aortic cross clamping
INRPRAE Prothrombin paramemeter coagulation pre operation
APTTPRAE Activated partial thromboplastin time pre operation
FIBPRAE Fibrinogen level pre operation
ATPRAE Activated prothrombplastin time pre operation
TCPRAE platelet count pre operation
HCTPRAE Hematocrit pre operation
kACTPRAE Kaolin activated clotting time pre operation
gbACTPRAE glass bead activated clotting time pre operation
CRPRAE Clot rate pre operation
PFPRAE Platelet function pre operation
FIBPOST Fibrinogen level post operation
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Abbr Expanded-Explained
TCPOST Platelet count post peration
kACTPOST Kaolin Activation clotting time post operation
gbACTPOST glass bead activated clotting time post operation
CRPOST Clot rate post operation
PFPOST Platelet function post operation
RBCTOTAL Red blood cells given in total
PCTOTAL Platelet concentrate given in total
FFPTOTAL Fresh frozen plasma given in total
ICU Intensive care unit
FCOP Fibrinogen given during operation
FCIP Fibrinogen given in ICU
PCCOP Prothrombin complex concentrate given during operation
PCCIPS Prothrombin complex concentrate given in ICU
DRAIN12H Blood in drainage 12hours post operation
FFREE Patient having received no blood products
FIB Fibrinogen given
PCC Prothrombin complex concentrate given
RETHX Open thorax again
NEURO Neurological problem
INFARCTION Post operation myocardial infarction
IABP Intra aortic balloon pump
RRT Renal replacement therapy
EXTD Time to extubatin in days
VENTT Ventilation time in hours
IPSCH ICU length of stay
LOScorr Hospital length of stay
ICUMO ICU mortality
POMO Post op mortality
HOMO hospital mortality
INFTOTAL Total infections
KATH Catheter associated infections
PULM Pulmonary Infection
STERNAL Sternal infection
HWI Urinary tract infection
SEPSIS Sepsis
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A.2 Complete structures for the two periods
AGE
HOMO
SEX
LDHprae
HCTPRAE
CELLSAVER
FFPTOTAL
EURO
HAES
FFREE
BMI
HYPER
DMins
FIBPRAE
FIBRINOGEN
LVEF
COLD
ASA
PVOD DMoral
KREAprae
RRT
GOTprae
GPTprae
CLOP
ALTC
kACTPRAE INRPOST
DUAL
LIQ
STATUS
PCTOTAL
AKE
OPTIME
ANATIME
CPBTIME
DRAIN24h
COMB MKR
INRPRAE
COMPAORTA
FIBPOST
TCPOSTPULM
TCPRAE
RBCTOTAL
IPSD
HCTPOST
HCTDISCH
kACTPOST
PCC
RETHX
LOScorr
VENTT
Figure A.1: Complete final DAG for the before period.
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AGE
SEX
DMoral
KREAprae
HCTPRAE
EURO
TCPOST
FFREE
BMI
HYPER
FIBRINOGEN
LVEF
COLD
FIBPRAE
PVOD
kACTPRAE
GOTprae
ASA
GPTprae
LDHprae
ALTC
INRPOST
LIQ
STATUS
AKE
OPTIME
CPBTIME
COMB
ANATIME
COMPAORTA
PCTOTAL
FFPTOTAL
CELLSAVER
FIBPOST
HCTPOST
RRT
INRPRAE
TCPRAE
RBCTOTAL
DRAIN24h
HCTDISCH
kACTPOST
PCC
VENTTIPSD
LOScorr
PULM
Figure A.2: Complete final DAG for the after period.
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ABSTRACT 1	
Background:  2	
Implementing coagulation management algorithms based on Point-of-care testing 3	
devices (i.e. thromboelastography (TEG) and rotational thromboelastometry 4	
(ROTEM)) have been shown to be benefial, both in terms of reducing transfusion 5	
rates and occurrence of adverse patient outcomes. Information on implementing a 6	
Sonoclot based coagulation management algorithm is scarce. 7	
Methods:   8	
Observational study comparing the transfusion rates of red blood cells (RBC) and 9	
patient adverse outcomes in two cohorts before (2009 to 2011) and after (2013 to 10	
2015) implementation of a Sonoclot based coagulation management algorithm in 11	
1754 patients undergoing different types of cardiac surgery. The effect of cohort and 12	
19 predictors on transfusion of RBC was assessed by relative R2-values obtained by 13	
bootstrapping and a hurdle regression model, comprising a binomial and a Poisson 14	
count component. Association of predictors with post-operative infections was 15	
assessed with a logistic regression model. 16	
Results: 17	
The proportion of patients not receiving allogenic blood products increased from 18	
32.1 % (95 % CI [28.9 to 35.3] %) prior to 63.2 % (95 % CI [59.9 to 66.3] %) after 19	
implementing a Sonoclot coagulation management algorithm. While proportions of 20	
patients receiving RBC and PLT both decreased from 64.1 % (95 % CI [60.8 to 67.4]) 21	
to 33.4 (95 % CI [30.4 to 36.6]) and 34.7 (95 % CI [31.5 to 38.0]) to 16.1 (95 % CI 22	
[13.7 to 18.6]), respectively, the proportion of patients receiving fresh frozen plasma 23	
was increased from 2 % (95 % CI [1.2 to 3.2] to 9.9 % (95 % CI [8.1 to 12.1]). If 24	
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patients received any allogenic blood product, solely the median of RBC units 25	
received decreased from four to three units after implementing the coagulation 26	
management algorithm. A significant decrease in renal replacement therapy from 27	
12.4 % (95% CI [10.2 to 14.8]) to 7.9 % (95% CI [6.2 to 9.8]), in pulmonary from 28	
15.5 % (95% CI [13.1 to 18.1] to 7.1 % (95 % CI [5.5 to 9.0]) and urinary infections 29	
from 4.0 % (95 % CI [2.8 to 5.6] to 1.3 % (95 % CI [0.7 to 2.3] was detected.   30	
Conclusion: 31	
The implementation of a Sonoclot based coagulation management algorithm was 32	
found to be beneficial for both a reduction in transfusion rates and a decrease in 33	
renal replacement therapies and post-operative infections. 34	
 35	
 36	
KEYWORDS 37	
Sonoclot, point-of-care devices, visco-elastic measurement, coagulation, cardio-38	
pulmonary bypass, heparin, bleeding, cardiac surgery, risk factors infection, RBC 39	
transfusion needs  40	41	
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 41	
INTRODUCTION 42	
Bleeding and the associated transfusion of blood products is a major concern in 43	
patients undergoing cardiac surgery. Both, bleeding and transfusion have been 44	
shown to be independent risk factors for increased postoperative morbidity and 45	
mortality in this patient group resulting in increased hospital costs. The relationship 46	
between RBC and post-operative infections remains elusive with controversial 47	
findings [1–8].  48	
A wide range of guidelines on peri-operative blood transfusion exist, which may 49	
rather reflect expert opinion than evidence-based decision-making [9]. Typically, 50	
transfusion rates of red blood cells (RBC) are larger when management of bleeding 51	
is at the clinician’s discretion [3,10].  When a liberal transfusion strategy with the 52	
same thresholds for both gender is followed, women may have a higher transfusion 53	
rate and be presumably over transfused [11]. Transfusion rates differ markedly in 54	
different hospital settings even after adjusting for patient characteristics and 55	
operative data [12]. In the past years an increasing number of PBM (patient blood 56	
management) initiatives have been published [13,14], indicating that transfusions can 57	
be reduced while patient outcome is maintained or even ameliorates [15–19]. 58	
Different studies in the last decade demonstrated that the point-of-care (POC) 59	
coagulation management algorithms based on viscoelastic measurement techniques, 60	
predominantly the thrombelastometry (ROTEM) and thrombelastography (TEG) 61	
combined with platelet function tests i.e. blood impedance aggregometry (Multiplate) 62	
are associated with a reduction of transfusion requirements and therefore in 63	
decrease morbidity (such as transfusion associated adverse events or 64	
cerebrovascular insults) and mortality [10], [3,20–22]. However, so far no coagulation 65	
management algorithm using another viscoelastic measurement technique, the 66	
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SONOCLOT analyzer, has been published. Based on our experience with this 67	
technique in different studies and the daily practice for more than ten years we 68	
developed and implemented a SONOCLOT based algorithm in cardiovascular 69	
surgery predominantly for the use of specific coagulation factors (fibrin concentrate 70	
and prothrombin complex concentrate) [23–25].  71	
Aim of this quality control study was to assess if patient cohorts before and after 72	
implementing an coagulation management algorithm differed in the transfusion of 73	
blood products, the administration of coagulation factors and the related outcome 74	
while adjusting for potential risk factors.  75	
 76	
 77	
MATERIAL AND METHODS 78	
Study setting and patient population 79	
Patient and procedure related data of cardiac surgery procedures at the Triemli City 80	
Hospital, Switzerland are recorded since 2007 in a dedicated database (Dendrite 81	
system) with the approval of the institutional research ethics board (Kantonale 82	
Ethikkommission Zurich, Switzerland; KEK Nr. StV 1-2007 SPUK Chirurgie) and 83	
patient informed consent. The full range of cardiac surgical interventions except heart 84	
transplantation are performed in this hospital: The off-pump approach is used for 85	
routine coronary artery bypass grafting. The main types of heart surgery performed 86	
include coronary artery bypass grafting (CABG), aortic valve procedures (av), mitral 87	
valve procedures (mv), combined procedures (comb) and aortic procedures (ao).   88	
When conversion to cardio-pulmonary bypass (CPB) is required, the beating heart 89	
technique under normothermia is applied. Open-heart surgery is done on CPB under 90	
moderate hypothermia (28 to 32 °C). Data analysis focusing on coagulation 91	
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management using a dedicated algorithm in the present quality control study was 92	
done for 1754 out of 2199 consecutive patients undergoing cardiac surgery after 93	
additional ethics board approval (Kantonale Ethikkommission Zurich, Switzerland; 94	
KEK-ZH-Nr. 2015-0633, BASEC Nr. 2015-00038) comprising the prior cohort from 95	
2009 to 2011 and the post cohort from 2013 to 2015. 96	
 97	
Red blood cell transfusion  98	
Anesthesia and intensive care were performed according to standardized protocols.  99	
Fluid management was done with lactated Ringer’s solution (Laboratory Dr. Bichsel 100	
AG, Switzerland) and synthetic colloids (Physiogel balanced, B. Braun Medical AG, 101	
Melsungen, Germany). Red blood cells (RBC) were transfused intraoperatively at 102	
hematocrit (HCT) levels below 25% (preserved left ventricular function) or below 28% 103	
(left ventricular function ≤ 30%, emergency operations), respectively. 104	
 105	
Prealgorithm coagulation management  106	
Based on standard activated clotting time (kaolin, kACT). Detailed technical aspects 107	
of Sonoclot technology have been described previously [23].  108	
 109	
Coagulation management algorithm 110	
The concept is depicted in figure 1 and described in [24,25]. 111	
 112	
Outcome parameters 113	
Primary outcome parameters: the amount of red blood cells given (in units) per 114	
patient. 115	
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Secondary outcome parameter: incidence of post-op infections.  116	
 117	
Statistical analysis 118	
All analyses were performed with the software package R [26], version 3.3.3. To 119	
compare patient-related demographic, pre-, peri- and postoperative data prior and 120	
post implementation of the coagulation management algorithm (cmalgorithm), 121	
descriptive statistics and univariable analysis were performed. Based on the format 122	
and distribution of the data, either Fisher’s exact test, t-tests or Wilcoxon rank sum 123	
test were applied. To quantify a significant difference between the two patient cohorts 124	
either an odds ratio with a 95 % confidence interval, a 95 % confidence interval for 125	
the difference between the means, or a 95 % confidence interval for the difference 126	
between medians is given. The latter one was obtained by 10’000 bootstraps with the 127	
package boot [27] using the percentile approach. 128	
To assess if the two cohorts prior and post implementing the cmalgorithm differed 129	
significantly in their amount of red blood cells given, while controlling for other 130	
potential influential factors, two different approaches were chosen. First, after a 131	
continuity-corrected log-transformation of the units of red blood cells given, the 132	
following predictors were included in the analysis: prior or post implementation of 133	
cmalgorithm, procedure time in minutes representing the time anaesthetized, five 134	
different types of surgery (cabg, av, mv, comb and comp), elective or emergency 135	
procedures (coded in 0 and 1), conversion to cardio-pulmonary-bypass with no (0) 136	
and yes (1), left-ventricular ejection fraction (LVEF) in %, administration of heparin 137	
preoperative with no (0) and yes (1) [LIQ], acetylsalicylic acid given preoperatively 138	
with no (0) and yes (1) [ASA], administration of clopidogrel preoperatively with no (0) 139	
and yes (1) [CLOP], administration of other platelet inhibitors with no (0) and yes (1) 140	
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[ALTC], body mass index (BMI), age in years, sex, preoperative hematocrit,  141	
preoperative platelets in 109/l,  international normalized ratio (INR), preoperative 142	
activated partial thromboplastin time (aPTT) in sec, preoperative fibrinogen in mg/dl, 143	
preoperative creatinine in µmol/l and preoperative alanine-aminotransferase in IU/l. 144	
To check for multicollinearity, variance inflation factors were assessed with the R 145	
package usdm [28]. Subsequently, only predictors with values below two were 146	
included in the analysis. The aim of this first analytical approach was to describe the 147	
“relative importance” or association of each of the predictors regarding the amount of 148	
red blood cells given. The importance of each of the predictors in the model was 149	
considered in form of a R2 value that is the ratio of the explained to the total variance 150	
in linear regression models. The relative R2 value refers to the ratio of the explained 151	
variance of the respective predictor to the total variance explained by the model. 152	
Point estimates and 95% confidence intervals for relative R2 values were obtained by 153	
bootstrapping (10’000 bootstraps) using the R package relaimpo [29] with both either 154	
including the respective predictor first or last.  155	
Since the number of red blood cells given contained an excess of zeros, in a second 156	
analytical approach, with the same predictors, a hurdle model using the package pscl 157	
[30] was chosen and its goodness-of-fit metrics (i.e. AIC and BIC) compared to other 158	
types of generalized models such as Poisson or negative binomial regression.  159	
Furthermore, to assess the association between potential risk factors and the 160	
incidence of infections postoperatively, a generalized linear model with a binomial 161	
link and logit function was chosen and performed with the R package MASS [31].  162	
 163	
RESULTS 164	
Descriptive statistics and univariable comparisons between the two patient 165	
cohorts 166	
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Patient-related demographic data, as well as preoperative medication and standard 167	
lab values of 1754 patients without missing values undergoing cardiac surgery before 168	
and after implementation of the cmalgorithm are summarized in Table 1. With regard to 169	
sex, age, BMI, and EUROScore no significant differences were detected between the 170	
prior and post cohort. LVEF was found to be significantly increased for the cohort 171	
after cmalgorithm implementation with a 95% CI of the difference of [0.03 to 2.5] %. 172	
Within the four different types of preoperative medication recorded, aspirin salicylic 173	
acid, heparin, clopidogrel or other platelet inhibitors and, only clopidogrel was found 174	
to be given significantly less often in the post cohort with an OR of 0.48 (95% CI 175	
[0.32 to 0.70]).  176	
Concerning preoperative lab values creatinine, INR and haematocrit were found to 177	
be significantly increased in the post cohort with 95 % confidence intervals of 178	
differences in medians of [2 to 6] µmol/l and [0 to 0.02] INR and a 95 % confidence 179	
interval of difference in means of [0.17 to 1.13] %, respectively. In contrast, Alanine-180	
Aminotransferase and platelets were significantly decreased in the post cohort 181	
compared to the prior cohort with corresponding 95 % confidence intervals of their 182	
differences in medians of [1 to 4] IU/l and [0 to 16] times 109/l.  Activated partial 183	
thromboplastin time and fibrinogen did not differ significantly between the two cohorts.  184	
 185	
The interventional times, i.e. duration of anaesthesia, operation time and CPB time, 186	
were all significantly reduced in the post cohort (table 2) with the respective 95% 187	
confidence intervals of difference in cohort medians of [15 to 35], [20 to 35] and [-14 188	
to 75] minutes. In contrast, the cross clamp time did not differ significantly between 189	
the two cohorts. The proportion of emergency procedures was significantly higher 190	
before implementing the cmalgorithm with an OR of 1.4 (95% CI [1.07 to 1.75]). Neither 191	
the proportion of conversion nor the proportions of the different types of cardiac 192	
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surgeries including the number of CABG differed significantly between the two 193	
cohorts (table 2). 194	
 195	
Regarding transfusions (table 3), significantly less ml of cell saver was re-transfused 196	
in the post cohort with a 95 % confidence interval of difference in medians of [50 to 197	
135]. Similarly, the proportion of patients having received any RBC versus none was 198	
significantly decreased in the post cohort with an OR of 0.28 (95% CI [0.23 to 0.34]). 199	
In patients who received RBC, significantly less units of RBC were administered in 200	
the post cohort with median of three units compared to four units in the prior cohort 201	
with 95 % confidence intervals of the medians of [2 to 6] for both cohorts. The 202	
proportion of patients with FFP was significantly increased in the post cohort with an 203	
OR of 5.3 (95 % CI [3.1 to 9.6]), the proportions of patients with platelet transfusions 204	
were significantly reduced with an OR of 0.36 (95 % CI of [0.28 to 0.45]). In patients 205	
which received either fresh frozen plasma or platelets there was no significant 206	
difference found between the two cohorts. The proportion of patients who did not 207	
receive any allogenic transfusion was significantly increased with an associated OR 208	
of 3.6 (95 % CI [3.0 to 4.4]). For the other coagulation products, fibrinogen and 209	
prothrombin complex C, the proportions of patients receiving these were significantly 210	
reduced after implementing the cmalgorithm with corresponding ORs of 0.45 (95 % CI 211	
[0.38 to 0.57]) and of 0.44 (95 % CI [0.35 to 0.54]), respectively. The group medians 212	
did not differ for these two products between these two cohorts. 213	
With respect to postoperative outcomes (table 4), the proportion of re-explored, of 214	
patients with myocardial infarction or with cerebrovascular insults did not differ 215	
significantly between the two cohorts. In contrast, the proportion of patients with renal 216	
replacement therapy was significantly reduced in the after cohort with an OR of 0.6 217	
(95% CI [0.43 to 0.84]). Similarly, the proportion of patients with an infection was 218	
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significantly reduced in the after cohort with an OR of 0.39 (95% CI [0.29 to 0.52]). In 219	
decreasing order pulmonary, urinary, sternal, sepsis and catheter associated 220	
infection were recorded, only the first two were significantly reduced in the post 221	
cohort. 222	
The duration of mechanical ventilation was significantly reduced in the patient cohort 223	
after implementation of the cmalgorithm with a 95% confidence of the difference in 224	
medians of [2 to 3]. The length of stay in ICU or in hospital was significantly 225	
increased after implementing cmalgorithm with a 95 % CI of the difference in medians 226	
less than a day and of [0 to 2] days. Mortality in ICU or in hospital did not differ 227	
significantly in both patient cohorts.  228	
 229	
Factors associated with amount of RBC given 230	
Relative importance: We used a bootstrap approach to determine relative R2 values 231	
of each predictor. Here, the implementation of the cmalgorithm was found - in all models 232	
including only one of the three interventional times each - to rank between the ranks 233	
two to four 4 out of 20 predictors. The first four ranks of the most important predictor 234	
were in all models taken by the variables interventional times, haematocrit, type of 235	
surgery and cohort. Still the total amount of variance explained by the model was 236	
only approximately 40 % (Figure 2).  237	
Hurdle model: Based on AIC and BIC, the model best fitting the data was a hurdle 238	
model with a negative binomial component to model counts of the units of blood cells 239	
given and a hurdle component to model the zeros (i.e. no red blood cells given) 240	
versus larger counts by a binomial distribution. In this regression model, the 241	
magnitude of the p values associated with the predictors was found to be in 242	
accordance with the results of the relative importance approach (supplementary file). 243	
More predictors are significantly associated with the zero hurdle component, i.e. 244	
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having received any number of blood cells versus none compared to the count 245	
component.  246	
Risk factors for infection post-OP 247	
Resulting from a logistic regression model the following predictors were found to be 248	
highly significantly associated with an infection post-operatively: implementation of 249	
cmalgorithm (OR of 2.5 with a 95% CI [1.8 to 3.6]) and RBC transfusion with an OR of 250	
1.12 (95% CI of [1.07 to 1.17]). Significantly associated were BMI, anesthesia time, 251	
creatinine, age and conversion to CPB (table 5). 252	
 253	
DISCUSSION 254	
Within the context of quality control and patient safety, this observational study aimed 255	
at comparing patient cohort before and after implementing a coagulation algorithm 256	
with regard to the amount of RBC given and post-operative outcomes. The proportion 257	
of patients which received RBC, PLT, fibrinogen and PCC was significantly 258	
decreased after implementation of the coagulation algorithm. In contrast, more 259	
patients received FFP after implementing the coagulation management algorithm. 260	
However, among the patients which received the specific blood products, the median 261	
amount did not differ between both cohorts with the exception of RBC where the 262	
median amount was four and three in the prior and post cohort, respectively. The 263	
decrease in RBC and PLT is in line with a number of studies showing beneficial 264	
effects of PBM [9,16,17,22,32,33], but an increase in the proportions of patients 265	
receiving FFP from 2 to 9.9%, while the median did not alter between the two cohort, 266	
is an unexpected finding. 267	
The individual effects of a number of potentially interrelated predictors on RBC 268	
administration are difficult to disentangle in a regression model. Still, based on two 269	
different statistical approaches, relative R2-values and a hurdle model, the difference 270	
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between the two cohorts was found to be significantly associated with the transfusion 271	
of RBC. The hurdle regression model, with a binomial as well as a count component, 272	
allows to differentiate, if the predictors are significantly with the binomial component 273	
(transfusion of RBC: yes or no) or with the amount of RBC units given. We chose the 274	
hurdle model to deal appropriately with an excess of zeros and over dispersion. 275	
Based on the hurdle model, it became evident that 12 out of 19 predictors are 276	
significantly associated with the transfusion of RBC, but only six with the amount of 277	
RBC given. Longer procedural times, no coagulation management algorithm 278	
implemented, lower pre-operative haematocrit, increasing age, lower BMI, higher 279	
pre-operative creatinine, being an emergency surgery, being female, conversion to 280	
CBP, pre-operative Alanin-Aminotransferase, and higher pre-operative INR were all 281	
associated with a significantly higher odds to receive RBC. Regarding the count 282	
component, only procedural times, pre-operative haematocrit, BMI, emergency 283	
procedure and conversion were significantly associated, in the same direction as the 284	
binomial component, with the amount of RBC units given. Additional in the count 285	
component, higher LVEF values were associated with a lower amount of RBC units 286	
given. 287	
Although the two cohorts differ significantly in a number of variables, most of the 288	
detected differences are clinically not considered relevant. Notable exceptions are 289	
Clopidogrel, which is administered significantly less often in the post cohort as well 290	
as the procedural times and the number of emergency surgeries, which are all 291	
reduced in the post cohort. This study is an observational study comprising 292	
observations from patient data collected in two different time periods. With the aim to 293	
assess the relative effect of each predictor, we decided not to use any approach 294	
involving matching or propensity scores. 295	
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Comparing the two cohorts, re-exploration rate, myocardial infarction, cerebro-296	
vascular insults did not differ significantly. In contrast, renal replacement therapy, 297	
pulmonary and urinary infection occurred significantly less often after implementing a 298	
coagulation management algorithm. Other types of infection (i.e. sternal, catheter 299	
associated and sepsis) occurred also less often, but were not significant, presumably 300	
due to small sample size.  301	
The beneficial effect of cohort, with the post cohort performing better than the prior 302	
cohort, could be due to a number of reasons: the coagulation management algorithm 303	
itself, but presumably also other changes in the two time periods which may have 304	
occurred. Still in the context of quality control and patient safety, we are confident 305	
that despite differences in the patient characteristics in the two cohorts, that the 306	
reduction in transfusion and subsequently costs, while improving with regard to 307	
patient safety (infections) are true and not spurious findings. Other reasons 308	
explaining, the beneficial effects on transfusion need and outcomes, may be an 309	
increased awareness of transfusion behaviour due to implementing a new 310	
coagulation management algorithm [15,34].   311	
 312	
LEGENDS TO FIGURES 313	
 314	
Figure 1 315	
Title:  316	
Coagulation management algorithm based on Sonoclot in cardiac surgery 317	
 318	
Footnote:  319	
ACT = Activated clotting time, ADP = Adenosine Diphosphate, AUC = Area under the 320	
curve, CR = Clot rate, FFP = Fresh frozen plasma, gbACT = glass bead-activated 321	
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clotting time, hepgbACT= glass bead-activated clotting time with heparinase. kACT = 322	
kaolin-activated clotting time, PC = Platelet concentrate, PCC = Prothrombin complex 323	
concentrate, PF = Platelet function, PT = Prothrombin time 324	
 325	
 326	
Figure 2 327	
Title:  328	
Risk factors for perioperative RBC administration. Here the relative R2-values, the 329	
ratio of the explained variance of the respective predictor to the total variance 330	
explained by the model obtained by bootstrapping are shown. 331	
 332	
Footnote:  333	
ALAT = Alanin-Aminotransferase, aPTT = Activated Partial Thromboplastin Time, 334	
ASA = Aspirin Salicylate Acid, BMI = Body mass index, CPB = Cardiopulonary 335	
bypass, HCT = Hematocrit, INR = International Normalized Ratio, LVEF = Left 336	
Ventricular Ejection Fraction 337	
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Table 1: Patient characteristics and preoperative standard lab values 
__________________________________________________________________ 
 Before After P 
 (n = 839) (n = 915) 
___________________________________________________________________ 
Patients 
F/M ratio n/n (%) 211/628 (25.1) 200/715 (21.8) 0.114F 
 95% CI [22.2;28.2] [19.2;24.7] 
Age in years median (IQR) 68 (60,70) 68 (59,75)  0.652T 
BMI in kg/m2 median (IQR) 26.6 (24.2,29.7)  26.5 (24.2,29.4) 0.208T 
LVEF in % median (IQR) 60 (47,65) 60 (50,65) 0.044T 
EUROScore median (IQR) 6 (3,8) 6 (4,8) 0.984T 
 
Preoperative Medication 
ASA n (%)     535 (63.8) 588 (64.3) 0.842F 
 95% CI     [60.4;67.0] [61.1;67.4] 
Clopidogrel n (%)     82 (9.8) 45 (4.9) < 0.001F 
 95% CI     [7.8;12.0] [3.6;6.5] 
Other platelet inhibitors n (%)     121 (14.4) 133 (14.5) 0.999F 
 95% CI     [12.1;17.0] [12.3;17.0] 
Heparin n (%)     153 (18.2) 173 (18.9) 0.759F 
 95% CI    [15.7;21.0] [16.4;21.6] 
 
Preoperative Lab 
Creatinine                     median (IQR)  77 (67,89) 81 (70,96)  < 0.001W 
umol/lit     
ALAT in IU/lit median (IQR) 23 (16,33) 20 (15,31) < 0.001W 
INR median (IQR) 1.02 (0.98,1.08)   1.03 (0.99,1.09) 0.044W 
aPTT in sec median (IQR) 31 (29,39) 31 (29,36) 0.471W 
Fibrinogen in mg/dl median (IQR) 367 (304,440)  358 (304,416) 0.067W 
Platelets in 109/lit median (IQR) 215 (181,263)  209 (172,246) < 0.001W 
HCT in % median (IQR) 40 (37,43) 41 (38,43) 0.006T 
___________________________________________________________________ 
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ALAT = Alanin-Aminotransferase, aPTT = Activated Partial Thromboplastin Time, 
ASA = Aspirin Salycilate Acid, BMI = Body mass index, F/M ratio = Female/Male ratio, 
HCT = Hematocrit, INR = International Normalized Ratio, LVEF = Left Ventricular 
Ejection Fraction 
F = Fisher’s exact test, T = t-test, W = Wilcoxon rank sum test 
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Table 2: Operation related data 
___________________________________________________________________ 
 Before After P 
 (n = 839) (n = 915) 
___________________________________________________________________ 
 
Interventional times 
Anesthesia time in min    median (IQR) 390(335,450) 370(324,420) <0.001W 
Surgery time in min median (IQR) 250(210,300)  225(180,270) <0.001W 
CPB time in min median (IQR) 68(0,125) 56(0,114) 0.039W 
 
Interventions 
Emergency procedures n (%) 182 (21.7) 154 (16.8) 0.011F 
 95% CI [18.9,24.6] [14.5,19.4] 
CABG n (%) 412 (49.1) 479 (52.3) 0.181F 
 95% CI [45.7,52.5] [49.0,55.6] 
Conversion rate n (%) 30 (3.6) 39 (4.3) 0.539F 
 95% CI [2.4,5.1] [3.0,5.8] 
AV procedures n (%) 165 (19.7) 156 (17.0) 0.174F 
 95% CI [17.0,22.5] [14.7,19.6] 
MV procedures n (%) 55 (6.5) 56 (6.1) 0.768F 
 95% CI [5.0,8.4] [4.6,7.9] 
Combined procedures n (%) 156 (18.6) 151 (16.5) 0.258F 
 95% CI [16.0,21.4] [14.1,19.1] 
Aortic procedures n (%) 108 (12.3) 103 (11.8) 0.769F 
                95% CI           [10.1,14.7]    [9.8,14.1]  
___________________________________________________________________ 
AV = Aortic Valve, CABG = Coronary Artery Bypass Grafting, CPB = Cardio-
Pulmonary Bypass, F = Fisher’s exact test, W = Wilcoxon rank sum test 
 
 
 
 
Table 3: Transfusions 
___________________________________________________________________ 
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 Before After P 
 (n = 839) (n = 915) 
___________________________________________________________________ 
Autologous transfusions 
Cell saver re-transfusion median (IQR) 520 (330,700) 430 (300,700) <0.001W 
in ml 
 
Allogenic transfusions 
RBC 
Patients with RBC  n (%) 538 (64.1)  306(33.4) <0.001F 
 95% CI [60.8,67.4] [30.4,36.6] 
If RBC received median (IQR) 4(2,6) 3(2,6) 0.027W    
 
FFP  
Patients with FFP  n (%) 17(2.0) 91(9.9) <0.001F 
 95% CI [1.2,3.2] [8.1,12.1] 
If FFP received median (IQR) 4(2,4) 4(2,8) 0.306W 
 
PLT    
patient with PLT n (%) 291(34.7) 147(16.1) <0.001F 
 95% CI [31.5,38.0] [13.7,18.6] 
If PLT received median (IQR) 2(1.5,2.0) 2(1,3) 0.809W 
 
Free of transfusion n (%) 269 (32.1) 578 (63.2) <0.001F 
                                         95% CI  [28.9,35.3] [59.9,66.3]   
 
Other coagulation products 
patient with Fib n(%) 506(60.3) 379(41.4) <0.001F 
                                         95% CI [56.9,63.4] [38.2,44.7] 
If Fib received median (IQR) 2(2,4) 2(2,4) 0.180W 
 
PCC in U/patient  
patient with PCC n(%) 343(40.9) 213(23.3) <0.001F 
                                         95% CI [37.5,44.3] [20.6,26.1]  
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If PCC received median (IQR) 1200(600,1200)      1200(600,1800) 0.264W 
 
_________________________________________________________________ 
FFP = Fresh Frozen Plasma, PLT = Platelet Concentrate, PCC = Prothrombin 
Complex Concentrate, RBC = Red Blood Cells 
F = Fisher’s exact test, W = Wilcoxon rank sum test 
 
 
Table 4: Postoperative Outcome 
___________________________________________________________________ 
 Before After P 
 (n = 839) (n = 915) 
___________________________________________________________________ 
 
General 
Re-exploration rate n (%) 68 (8.1) 67 (7.3) 0.591F 
                                         95% CI [6.4,10.2] [5.7,9.2] 
 
Myocardial infarction n (%) 12 (1.4) 14 (1.5) 0.999F 
                                         95% CI [0.7,2.5] [0.8,2.5] 
 
Cerebrovascular Insult n (%) 19 (2.3) 11 (1.2) 0.098F 
                                         95% CI [1.4,3.5] [0.06,2.1] 
 
Renal replacement therapy n (%) 104 (12.4) 72 (7.9) 0.002F 
                                         95% CI [10.2,14.8] [6.2,9.8] 
 
Infection 
Pulmonary n (%) 130 (15.5) 65 (7.1) <0.001F 
                                         95% CI [13.1,18.1] [5.5,9.0] 
 
Catheter associated n (%) 9 (1.1) 4 (0.4) 0.164F 
                                         95% CI [0.5,2.0] [0.1,1] 
 
Sternal n (%) 18 (2.1) 12 (1.3) 0.200F 
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                                         95% CI [1.3,3.7] [0.7,2.3] 
 
Urinary n (%) 34 (4.0) 12 (1.3) <0.001F 
                                         95% CI [2.8,5.6] [0.7,2.3] 
 
Sepsis n (%) 19 (2.3) 11 (1.2) 0.098F 
                                         95% CI [1.4,3.5] [0.6,2.1] 
 
Infection total n (%) 177(21.1) 86 (9.4) <0.001F 
                                         95% CI [18.4,24.0] [7.6,11.5] 
 
 
Postoperative times 
Duration of mech.    
Ventilation in h median (IQR) 7(5,15)         5(4,8)  <0.001W 
 
 
ICU length of stay in d median (IQR) 1(0.67,1.67) 1(1,1.67) <0.001W 
 
Hospital length of stay in d median (IQR) 8(6,11) 8(7,12) <0.001W 
 
 
Mortality 
ICU < 24h n (%) 19 (2.3) 15 (1.6) 0.388F 
 95% CI [1.4,3.5] [0.9,2.7] 
 
ICU Total n (%) 24 (2.9) 18 (2.0) 0.274F 
 95% CI [1.8,4.2] [1.2,3.1] 
 
Hospital stay n (%) 45 (5.4) 35 (3.8) 0.137F 
 95% CI [3.9,7.1] [2.7,5.3] 
___________________________________________________________________ 
ICU = Intensive Care Unit 
F = Fisher’s exact test, W = Wilcoxon rank sum test 
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Table 5: Risk factors for postoperative infections 
___________________________________________________________________ 
Predictors odds ratio 95% CI  p 
___________________________________________________________________ 
No algorithm 2.535 [1.813 to 3.572] <0.001 
RBC transfusion 1.118 [1.074 to 1.167] <0.001 
BMI 1.053 [1.018 to 1.088] 0.002 
Anesthesia time 1.002 [1.001 to 1.004] 0.005 
Preop creatinine 1.004 [1.001 to 1.008] 0.008 
 
Age 1.025 [1.006 to 1.045] 0.012 
Conversion to CPB 2.115 [1.057 to 4.025] 0.027 
Platelet inhibitors 1.488 [0.997 to 2.197] 0.049 
Preop platelet count 0.998 [0.995 to 1.000] 0.063 
Preop fibrinogen level 1.001 [1.000 to 1.003] 0.076 
Preop ALAT 1.003 [0.999 to 1.007] 0.113 
Preop INR 1.017 [0.991 to 1.041] 0.139 
Type of surgery*             0.232 
Clopidogrel 0.719 [0.389 to 1.267] 0.270 
EURO Score                     1.035           [0.967  to 1.107]                   0.315 
PCC administration 1.000 [0.9999 to 1.0003] 0.316 
Preop HCT 0.986 [0.956 to 1.018] 0.376 
Sex 1.171 [0.805 to 1.693] 0.406  
ASA intake 0.885 [0.623 to 1.260] 0.494 
Fibrinogen administration  0.973 [0.896 to 1.053] 0.496 
Preop aPTT 1.001 [0.997 to 1.005] 0.531 
Emergency procedures 0.874 [0.551 to 1.369] 0.562 
LVEF 1.003 [0.991 to 1.016] 0.594 
___________________________________________________________________ 
ALAT = Alanin-Aminotransferase, aPTT = Activated Partial Thromboplastin Time, 
ASA = Aspirin Salicylate Acid, AV = Aortic valve, BMI = Body mass index, CPB = 
Cardiopulonary bypass, HCT = Hematocrit, INR = International Normalized Ratio, 
LVEF = Left Ventricular Ejection Fraction, MV = Mitral valve, PCC = Prothrombin 
Complex Concentrate, *based on a likelihood-ratio test  
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Figure 1 
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INTRODUCTION
Blood transfusion rates are particularly high in cardiac surgeries [1,2]. A high variability in
red blood cell (RBC) transfusion exists even after adjustment for patient demographic data,
comorbidity  and  operative  data  [3].  Next  to  increased  costs,  transfusion-related  adverse
outcomes  including  raised  major  concerns  [4].  A randomised  trial  comparing  restrictive
transfusion cut-off for haemoglobin (<7.5 g/dl)  and liberal  (<9g/dl)  one,  showed no clear
difference in cost-effectiveness and QALYS [5].  Transfusion of one or two units of RBC did
not affect mortality in patients undergoing isolated coronary artery bypass graft (CABG) [6].
This finding was also substantiated by a systematic review [7]. However, in patients with
acute coronary syndrome, transfusion of ≥4 units RBC after CABG was found to be strongly
associated  with  mortality  [8].  Differences  when  assessing  the  impact  of  red  blood  cell
transfusion  on  mortality  can  explained  partially  by  differences  in  observational  versus
randomised clinical trials [9].
Typically,  adverse  outcomes  in  patients  undergoing  cardiac  surgery  are  significantly
associated with a triad of factors: patient related demographic data including co-morbidities,
operation-related patient data and transfusion-related patient data. 
Prediction models for postoperative pneumonia, the most prevalent of all-hospital-acquired
infections after CABG surgery, included a number of patient demographic and comorbidity
data as well as peri-operative data [10,11]  and transfusion-related data, esp. RBC were found
to impact pneumonia rates after CABG [12]. Amongst patient demographic data, BMI was
found to  be  significantly  associated  with  pulmonary  morbidity  [13].  Deep sternal  wound
infections were found to be associated with transfusion of ≥ 4 units  of RBC and chronic
infections [14].  Post-operative infection has been found to be associated with a  high-risk
profile [15] and with RBC transfusion [16].
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Renal  replacement  therapy  after  aortic  dissection  was  shown  to  be  associated  with
preoperative creatinine level,  cardiopulmonary bypass time and amount of red blood cells
transfused intra-operatively [17]  and with pre-operative co-morbidities  and intra-operative
data [18]. Acute kidney injury after aortic valve replacement was found to be associated with
RBC transfusion, obesity and prolonged cardiopulmonary bypass times [19]. Similarly, in a
matched case-control study, RBC transfusion as found to be associated with acute kidney
injury [20].
A number  of  so-called  patient  blood  management  (PBM)  initiatives,  aiming  at  reducing
transfusion  rates  and improving patient  outcome have  been  published [21–26].  The ESA
(European Society of  Anaesthesiology)  has  officially  endorsed a  practical  implementation
guide for hospitals to support PBM in the EU [27]. In the US, PBM programs were reported
in 37.8% US AABB hospitals in 2013 [28]. 
Coagulation  management  algorithms  based  on  point-of-care  (POC)  viscoelastic  testing
resulted  in  reduced  transfusion  rates  of  RBC,  plasma  and  platelets  compared  to  clinical
judgement  combined  with  conventional  laboratory  tests  [29–33].   Thromboelastography
(TEG)  and  rotational  thromboelastometry  (ROTEM)  have  been  described  to  reduce  the
proportions  of  patients  receiving  allogenic  blood  products  [34].  Additionally,  the  overall
mortality was found to be decreased, but the quality of evidence based on the available studies
was considered to be low [34]. Another review indicated no additional benefit in important
clinical outcomes beyond reduction in transfusion rates [35]. In a randomized clinical trial,
solely the RBC transfusion rates were found to be reduced [36]. In a single-center cohort
study, first line administration of coagulation factor concentrates combined with POC testing
gave evidence for a decrease in allogenic blood transfusions and adverse events  [37]. 
A lack  of  understanding on how transfusion  might  be  related  to  morbidity  and mortality
becomes  evident,  i.e.  the  effect  of  patient  related  data,  with  patients  displaying  different
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predicted risks of mortality and the role of RBC and other allogeneic blood transfusion, while
the  latter  was  hypothesized  to  be  secondary  to  the  former  [38].  When  aiming  to  reduce
hospital-related costs  and improving patient  outcome in an evidence-based approach,  one
encounters the difficulty to disentangle the single effects of transfusion procedures, operation
data, as well as patient demographic data including co-morbidities in cardiac surgeries. The
relationship  between  these  risk  factors  represent  a  complex  interaction,  which  is  poorly
understood [39]. 
In  the context  of  risk factor  analysis,  traditional  regression approaches  including logistic,
linear and Poisson regression are widely used and well-known to clinicians.  Amongst the
most widely reported measurements for statistical associations between a potential risk factor
and a dichotomous outcome, e.g. needing or not a renal replacement therapy after cardiac
surgery are odds ratios (OR) resulting from logistic regression models. Based on the scale of
the potential risk factor, e.g. binary meaning absence (0) or presence (1) of pre-existing renal
impairment or continuous, e.g. creatinine in mg/dl, an odds ratio of 2 is interpreted as the odds
receiving  renal  replacement  therapy  is  twice  as  high  in  patients  with  pre-existing  renal
impairment  compared  to  those  without.  Similarly,  for  a  continuous  predictor,  each  unit
increase  in  mg/dl  creatinine,  the  odds  of  receiving  renal  replacement  therapy  would  be
increased by two. Likewise, if the outcome is continuous, the effect of a binary predictor,
would be the difference in means (e.g. classical t-test) and the effect of a continuous predictor
is assessed in the form of a regression coefficient, describing the effect of a one unit increase
in the predictor on the outcome. Furthermore, in the context of Poisson regression, where the
outcome are counts, e.g. units of RBC transfused intraoperatively, a binary predictor being an
emergency or an elective surgery, is interpreted on the multiplicative scale. More precisely, an
odds ratio of 4 for being an emergency versus an elective case, would indicate that the units of
RBC transfused are four times higher in elective cases. 
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Classical,  frequentist  regression  approaches,  including  p-values  and  confidence  intervals,
originate from experimental settings developed by pioneers like Ronald Fisher in the first half
of last century. In this setting, it is assumed, that the investigator is able to control for all
factors leading to a potentially balanced data set.  This assumption would imply for a risk
factor study, that the numbers of patients presenting specific risk factors, e.g. being smokers
or not, is the same in males and females or in diabetic and non-diabetic individuals, or in
emergency and elective surgeries. While having clearly its merits in many fields of clinical
epidemiology,  the  classical  frequentist  regression  approach  including  many  different
predictors in observational studies is actually questionable for a number of reasons [40,41].
The frequent  (mis-)use  of  p-values  to  assess  clinical  significance  and subsequently  claim
evidence has been deployed for a long time by statisticians [37,42]. In the context of the so-
called  reproducibility  crisis,  classical  medical  data  analysis  relying  on  p-values  and
hypothesis testing is continuously criticized [43].  A radical  decision to ban all p-values in
publications was taken by the  Journal Basic and Applied Social Psychology [44]. Recently,
the ongoing debate led to a formal statement of the American Statistical Association aiming at
“clarifying several widely agreed upon principles underlying the proper use and interpretation
of the p-value” [45].
Two technical aspects are worth mentioning when analysing observational data assessing the
effect  of  multiple  potential  risk  factors  or  predictors  on  outcomes  like  amount  of  blood
products administered and occurrence of infections postoperatively associated. First, finding
the best model or deciding which predictor should actually be included in a multivariable
analysis  can  be  challenging  and  overfitting,  e.g.  finding  spurious  –  non  reproducible  –
significant associations, is an ever present issue [46] in regression analysis.  Although being
described  a  long  time  ago,  Simpson’s  paradox,  consisting  of  finding  an  effect  or  trend
between  groups,  which  disappears  or  may  even  be  reversed  once  groups  are  combined,
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continues to be involved in biased and misleading results [47]. Second, in studies aiming at
assessing the effect of implementing coagulation management algorithm, most often there are
a number of relevant outcomes: e.g. amount of different blood products given, incidence of
different types of infections post-operatively, myocardial infarction, cerebrovascular insults,
length of hospital or ICU stay and mortality. In consequence, an analysis, allowing not only
for  including  multiple  predictors  (multivariable)  but  simultaneously  multiple  outcomes
(multivariate),  is  warranted.  Performing a PubMed literature  research  using  the following
MeSH  terms  (cardiac,  surgery,  blood,  transfusion,  risk,  factor,  infection)  yields  36
publications from 2010 onwards. A number of papers uses matching [14,38,48] or propensity
scores  [15,16,49]  to  obtain  groups  of  patients  which  are  balanced  with  regard  to  some
characteristics. The downside from this approach is, that it is no longer possible to assess the
effect of these variables, being potentially a risk factor, which have been used for matching on
the outcome of interest.  Although in several  papers  out of the 36 papers found, different
clinical  outcomes  are  explicitly  mentioned  as  research  interest,  typically  each  clinical
outcome is analysed separately by – depending on the data format – multivariable regressions.
One attempt is made to capture the information contained in several outcome variables of
interest by composite end points [50], thus leading to a reduction in dimension.
Most clinicians use regularly Bayesian reasoning, not only in the form of predictive values as
a direct application of Bayes theorem, but also in clinical decision making [51]. Still the vast
majority of risk factor studies uses frequentist approaches as evidenced by the 36 publications
found. With increased computational power, complex Bayesian analyses relying on Monte
Carlo  Markov  chain  simulations  became  possible.  Bayesian  network  analysis,  a  form of
graphical  modeling,  has  mainly  been  developed  in  the  context  of  machine  learning  and
computing  science  [52–54]  .  Although  the  underlying  theoretical  concepts  of  Bayesian
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network modeling have been well established [55], this type of modeling is rarely seen in risk
factor studies. 
One  special  case  of  Bayesian  network  analysis,  the  so-called  additive  Bayesian  network
(ABN)  analysis  can  be  understood  as  a  multivariate  regression  with  all  variables  being
potentially statistically dependent, thus offering a far richer modelling framework compared
to  multivariable  regression  [56].  Results  of  ABN  analysis  are  displayed  in  the  form  of
graphical models, so called directed acyclic graphs (DAG). They consist of nodes, which are
the  variables  –  with  no  difference  made  between  predictors  and  outcomes  –  and  arcs
connecting them. While nodes from which arcs start to reach another node are names parents,
those nodes which receive arcs from another are named children. The resulting DAG is a
graphical representation of statistical associations between variables. Similarly to generalized
linear models, it is possible to quantify the association or effect size between to variables.
Performing  an  analysis  with  ABN  comprises  two  steps.  First,  including  all  variables  of
interest  and  then,  based  on the  data  at  hand,  obtain  a  so-called  globally  optimal  model.
Optimal means here that the number of potential parents is subsequently increased, meaning
that the complexity of the model is increased, while the marginal log-likelihood is used as a
measure of goodness-of-fit criterion [57]. In a subsequent assessment the posterior density of
each variable and dependency upon another variable will be assessed. The aim of this check is
to assure, that not only the globally best model was determined, but also that each variable
included contains enough information to be included. The second step consists of relying on
bootstrap approaches to handle appropriately overfitting and subsequently remove arcs, which
are found in less than 50 % of the bootstraps. 
In contrast to classical Bayesian networks, ABNs do not rely on expert opinion and use only
uninformative  priors  to  find  the  best  graphical  representation  of  the  data.  This  approach
relieves the clinical data analyst from separating different categories of clinical outcomes for
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analysis, while presumably the same data generating mechanisms (e.g. patient characteristics,
intervention-related data) actually may explain a the joint occurrence of a number of different
clinical relevant outcomes (e.g. amount of different blood products given, infections, renal
replacement therapy, myocardial infarction, length of stay in hospital or ICU and moratlity). 
For  this  study  we  used  data  analysed  previously  with  classical  multivariable  frequentist
methods (Hofer, pers. communication). The data were collected within a quality control study
the impact of implementing a coagulation management algorithm [58,59]. Assuming complex
relationships between patient demographic data including comorbidities and pre-medication,
patient data generated during surgery with administration of different blood products and the
occurrence of a number of adverse events in patients undergoing cardiac surgery, the aim was
to assess if  applying additive Bayesian network modeling would allow to disentangle the
effects of single factors simultaneously.   
MATERIAL and METHODS
Database
The  two  sets  of  data  (before  and  after  implementation  of  a  coagulation  management
algorithm) comprised 90 variables including demographic data, preoperative medication, lab
values,  data  recorded  during  surgery  and  afterwards,  number  of  types  of  blood  products
received  and  a  number  of  different  complications  as  well  as  length  of  hospital  stay  and
mortality. A detailed  description  of  all  variables  is  given  in  the  annex.  After  plausibility
checks and data cleaning 1754 patients were included in the analysis. The initial number of 90
variables was reduced to 54 for each period, after  assessing the computational difficulties
related to the size of the dataset. The reduction of the dataset was based on several criteria.
Less important variables were removed after agreement, as well as partially separated binary
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factors. Lab and diagnostic tool measurements at patient level, taken before and after surgical
operation were aggregated into one. Indications such as diabetes, with two separate binary
factors for oral and insulin medication, now are considered as one. Similarly, patients with
cardiac insufficiency in the past or present, ICU mortality and mortality during hospitalisation
period are reduced two one variable. 
Analysis
First to find an optimal DAG, the maximal number of parents of each node was subsequently
increased from 1 to 9 and marginal log-likelihood, assessing the goodness-of-fit was utilised
to determine the globally best model with the optimal number of parents. To discover the
optimal structure, a heuristic algorithm was used. Starting from a random starting structure
created by adding arcs randomly to an empty network, the algorithm performs a stepwise
search for an improved network, where three stepwise operations are possible: i) add an arc;
ii) remove an arc; iii) reverse an arc. The stepwise search is subject to a number of conditions,
first only moves that do not generate a cycle are permitted, secondly, a parent limit is imposed
which fixes the maximum number of parents which each child node can have, and thirdly, it is
possible to ban or retain arcs.  This heuristic algorithm was ran multiple times,  each time
starting from an initial random DAG resulting to a local optimum structure. After gathering all
locally best  DAGs, the majority consensus is  extracted,  in other  words,  only associations
appeared 50% of the times were kept. Excess arcs were discarded.  
 Next to posterior densities, which should look bell-shaped and integrate to one, the AUC
(area under the curve) of all posterior densities was also assessed.  (add data separation here?)
Subsequently 10’000 bootstraps were run and the final DAGS for both cohorts contain only
arcs which were retrieved in at least 50% of the bootstraps.
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The results will be presented in the form of DAGS. (Add likelihood equivalence: direction of
arcs).
RESULTS
Possible up to 4 parents, 54 variables, data separation, memeory
It was possible to obtain DAGS for both patient cohorts separately. 
In  Figure  1  and  2  the  Markov  blankets,  jointly  shown  for  all  variables  describing  the
administration of five different blood products given during surgery or in intensive care unit
(RBC, platelets, fresh frozen plasma prothrombine complex C, fibrinogen and absence of any
allogeneic blood prodcuct) as well as the complications post-OP (renal replacement therapy,
infection, re-thoracotomy, mortality and neurological sequelae) for both patient cohorts are
shown. 
Prior cohort blood products
RBC: Was found to be linked to six other variables. With more units of RBC transfused, the
the drained volume 24 h post-Op increased.  RBC transfusion rates  increased jointly  with
transfusion of paltelets. There was a positive association between hours of ventilation and
RBC transfused. Furthermore both endogeneous fibrinogen and kaolin-activated clotting time,
with  (more)  RBC transfused  being  associated  with  a  lower  fibrinogen  concentration  and
longer kaolin-activated clotting times.
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PCtotal: The amount of platelets transfused was linked to ten variables. Next to a positive
association with RBC, transfusion of platelets was also positively associated with fresh frozen
plasma  and  fibrinogen.  Patients  with  higher  platelet  counts  before  surgery  received  less
platelets.  Both  longer  surgery  and  anaesthesia  times  were  associated  with  more  platelets
transfused. Patients with emergencies compared to elective surgeries received more platelets.
Similarly, patients  with re-opening of the thorax received more platelets.  Receiving more
platelets was also associated with a higher odds for renal replacement therapy and a higher
mortality. 
FFPTotal: Fresh frozen plasma given in total is linked to 6 variables. Higher fresh frozen
plasma was given to male patients with hypertension, as well as it had a positive association
with cardiopulmonary bypass time and kaolin activated time in seconds prior the operation.
Fibrinogen: Units of Fibrinogen given in total is linked to 6 variables.  A negative association
was found for higher values of BMI and patients who did undergo a transfusion of the blood
products. An increased amount of Fibrinogen was given to patients with a re opening of the
thorax operation , as well as it was positively connected with higher cardiopulmonary bypass
times, Prothrombin complex concentrates and platelets given in total.  
PCC:  Prothrombin  complex  concentrate  given  in  total  was  linked  to  4  variables.  Higher
expected counts of Prothrombin complex concentrate  found to be assoaciated with higher
number of units of platelets and fibrinogen, as well as for patients that had an aortic valve
replacement procedure. Patients free of any blood transfusion product are expected to have a
lower number of Prothrombin complex concentrate units given.
FFREE: Patients that were free of allogenic blood products transfusions. FFREE was linked
to  9  variables  in  total.  The  odds  of  a  patient  being  free  of  transfusion  had  a  negative
association with increased anaesthesia time, cardiopulmonary bypass time, Euroscore, number
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of units of Prothrombin complex concentrate, Fibrinogen, Cellsaver(patient’s own blood re
transfused)  and  postoperative  measurement  of  endogenous  Fibrinogen.  Additionally,  a
negative association was found between being free of transfusion and having an Infection or a
re opening of the thorax procedure.  Last,  free of transfusion patients were found to have
higher post operative hematocrit value.  
Prior complications
RRT:  Renal  replacement  therapy   was  connected  with  6  variables.  Increased  odds  are
associated  with  increased  values  for  pre  operative  endogenous  creatinine  value  and  total
platelets  given,  while  decreased  odds  for  higher  values  of  post  operative  endogenous
Fibrinogen values.
Infection:  Several  indications  of  infections.  Linked  to  5  variables.  Includes  pulmonary,
sternal, catheter, urinary and sepsis. The odds of patients having an infection of several types
was increased by age and anaesthesia time while patients with no transfusion of the blood
products had lower odds of infection. Positive association was also found with length of stay
at the hospital and ventilation time.
RE-THX: Re opening of the thorax. 5 connections were discovered. Positive association of
patients  with  re  opened  thorax  was  found  with  24h  drainage,  platelet  units  given,  post
operation  International  normalized  ratio  (INR)  score  and Fibrinogen  given.  The  odds  for
patients with re opened thorax are decreased if they are free of transfusion. 
MORT: Mortality either in ICU or during hospitalisation is connected to 6 other variables.
The odds of mortality are associated with increased age and platelet in units given. Positive
association also found with ventilation time and post operative kaolin activated time while a
negative one with length of stay and International normalized ratio (INR) score. 
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Neurocerebro:  Neurological  problem  specific  to  cerebral  palsy  was  connected  only  to
Euroscore with higher odds for increased scores.
Post cohort blood products
RBC: Red blood cells units given in total was connected to 6 variables. A positive relationship
was found for increased platelets and fresh frozen given in units, while higher number of red
blood cells is expected for increased number of days spent in intensive care. Red blood cells
are also associated positively with mortality. 
Pctotal:  Platelet  units  given  in  total  were  connected  with  7  variables.  Increased  units  of
platelets are expected to be given to patients with a re opening of the thorax operation, a renal
replacement therapy and operation at the great vessels and aorta. Positive association was also
found with cardio pulmonary bypass time in seconds, Fibrinogen given, red blood cells given
and cellsaver (patient’s own blood re-transfusion) 
FFPTotal: Fresh frozen plasma was connected to 4 variables. More plasma is expected to be
given to patients with a re opening of the thorax procedure and surgery of the great vessels
and aorta. A positive association was found with red blood cells while patients with lower
hematocrit after operation are expected to have less fresh frozen plasma transfused.
Fibrinogen: Fibrinogen units given in total are linked to 5 variables. Patients who were free of
transfusion received less Fibrinogen while re opening of the thorax procedure increases the
units of Fibrinogen given. At the same time, a positive association was found with the volume
drained 24h, prothrombin complex concentrate in units and platelets given.
PCC: Prothrombin complex concentrate in units was linked with 4 variables. Patients with
cardiac insufficiency present or in the past as well as patients free of any transfusion of the
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various blood products are expected to have lower units of Prothrombin complex concentrate
given in total.
FFREE:  Patients  free  of  transfusion  of  the  various  blood  products  was  connected  to  6
variables.  The odds of  being free of  transfusion are increased with higher  values  of post
operative hematocrit value. Increased operation times in seconds, Euroscore, Fibringen units
and platelet units given decrease the odds of a patients being free of transfusion. Lastly, the
odds are decreased if a patient suffering from types of infection.
Post complications
RRT : Renal replacement therapy is linked to 6 variables. The odds of a patients having a
renal repalcement therapy are decreased for those being free of transfusions, while the odds
are increased with higher values of pre operative creatinine and platelet units given as well as
for increased length of stay in hospital, days spent in ICU and ventilation time.
Infection :  Several indications of infections. Includes pulmonary,  sternal, katheter, urinary
and sepsis. A positive association between length of stay at the hospital was found, while the
odds of infections were decreased for patients free of transfusion.
RE-THX : Re opening of the thorax procedure is linked to 8 variables.The odds of re opening
of the thorax procedure were increased for higher values of kaolin activated time in seconds
while the odds were decreased for patients with peripheral vascular occlusive disease. Positive
associations were also found with drainage 24h, fresh frozen plasma given in units, fibrinogen
given in units, ventilation time, days spent at ICU and mortality.
MORT ;  Mortality  during  hospitalisation  period  or  in  ICU was  connected  to  6  variables.
Positive links between mortality and age, re opening of the thorax procedure, red blood cells
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given  in  total,  ventilation  time  and  days  spent  in  ICU were  found.  Mortality  odds  were
decreased for patients who received clopidrogel,  an inhibitor that prevent blood clots  and
strokes – heart attacks. 
Neurocerebro: Neurological problem specific to cerebral palsy was linked only to Euroscore
with higher values uncover neurological problems.
Discussion
This study aimed to gain insights into the complex relationsships between the triad of factors:
patient related demographic data including co-morbidities, operation-related patient data and
transfusion-related patient data. It was possible to obtain dags with up to four parents, thus
presumably  not  the  complete  complexity  was  covered.  Still  within  this  approach  54^4
potential  different  DAGS  were  searched,  thus  offering  a  richer  modelling  framework
compared to classical frequentist approaches with are limited to a single outcome variable.
A number of associations founds are to be expected, e.g. higher 24 h drained volume with an
increase  in  transfusion  rates  and  with  re-thoracotomy  or  longer  procedural  times  being
associated with higher odds for infections, higher pre-Op Euro-Scores
While RBC was not found to be associated to infection in both patient cohorts, transfusion
rates of RBC were associated to mortality. Still, different explanations are possible. Critical-
ill patients will have a higher chance to die and/or RBC transfusion rates are associated with a
higher risk to die [38].. Ventilation-associated pneumonia has been described [60]. 
This analysis also highlighted the role of ventilation hours being positively associated with
higher  mortality, longer  hospital  stay  and higher  odds  for  renal  replacement  therapy and
infection. 
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Using additive Bayesian network modeling is an innovative and promising approach to gain 
insights into complex relationsships.
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